Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.

@article{Kaufman1998FinasterideIT,
  title={Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.},
  author={K. Kaufman and E. Olsen and D. Whiting and R. Savin and R. Devillez and W. Bergfeld and V. Price and D. Van Neste and J. Roberts and M. Hordinsky and J. Shapiro and B. Binkowitz and G. Gormley},
  journal={Journal of the American Academy of Dermatology},
  year={1998},
  volume={39 4 Pt 1},
  pages={
          578-89
        }
}
BACKGROUND Androgenetic alopecia (male pattern hair loss) is caused by androgen-dependent miniaturization of scalp hair follicles, with scalp dihydrotestosterone (DHT) implicated as a contributing cause. [...] Key MethodMETHODS In two 1-year trials, 1553 men (18 to 41 years of age) with male pattern hair loss received oral finasteride 1 mg/d or placebo, and 1215 men continued in blinded extension studies for a second year.Expand
Finasteride in the treatment of men with frontal male pattern hair loss.
TLDR
In men with hair loss in the anterior/mid area of the scalp, finasteride 1 mg/day slowed hair loss and increased hair growth. Expand
Finasteride: a review of its use in male pattern hair loss.
TLDR
Oral finasteride promotes scalp hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss, and is a new approach to the management of this condition, for which treatment options are few. Expand
Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily.
TLDR
Hair weight increased to a larger extent than hair count, implying that factors other than the number of hairs, such as increased growth rate (length and thickness of hairs) contribute to the beneficial effects of finasteride in treated men. Expand
Finasteride Treatment of Patterned Hair Loss in Normoandrogenic Postmenopausal Women
TLDR
Oral finasteride in a dosage of 2.5 mg/day or more may be effective for the treatment of pattern hair loss in postmenopausal women in the absence of clinical or laboratory signs of hyperandrogenism. Expand
Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies.
  • D. Whiting
  • Medicine
  • European journal of dermatology : EJD
  • 2001
TLDR
It can be concluded that finasteride prevents further hair loss by actually continuing to grow enough hair to preserve scalp coverage, and is a strong indication for prescribing it in early cases of androgenetic alopecia before much hair has been lost. Expand
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
TLDR
D doses of finasteride as low as 0.2 mg per day maximally decreased both scalp skin and serum DHT levels, which support the rationale used to conduct clinical trials in men with male pattern hair loss at doses of Finasteride between 0. Expand
Androgens and alopecia
  • K. Kaufman
  • Biology, Medicine
  • Molecular and Cellular Endocrinology
  • 2002
TLDR
It is suggested that MPHL and FPHL are distinct clinical entities, with disparate pathophysiologies, and studies that elucidate the molecular mechanisms by which androgens regulate hair growth would provide greater understanding of these differences. Expand
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
TLDR
In postmenopausal women with AGA, finasteride 1 mg/day taken for 12 months did not not increase hair growth or slow the progression of hair thinning. Expand
Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
TLDR
Finasteride 1 mg/day is the optimal dose for the treatment of men with male pattern hair loss and was subsequently identified for further clinical development. Expand
5α-Reductase Inhibitors in the Treatment of Androgenetic Alopecia
TLDR
Clinical studies in balding men demonstrated that treatment with finasteride reduced scalp DHT levels and led to improvement in scalp hair growth, confirming both the role of DHT in the pathophysiology of AGA in men and the utility of inhibiting DHT production in the treatment of men with AGA. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.
TLDR
In this study, male subjects treated with 5 mg/day finasteride for 4 weeks had significantly decreased concentrations of DHT in bald scalp, resulting in a mean level similar to the baseline levels found in hair-containing scalp. Expand
A hair growth questionnaire for use in the evaluation of therapeutic effects in men
TLDR
A questionnaire to measure patient-perceived changes in hair growth and appearance in clinical trials of medical intervention for androgenetic alopecia in men is developed and evaluated. Expand
PATTERNED LOSS OF HAIR IN MAN: TYPES AND INCIDENCE
  • J. Hamilton
  • Medicine
  • Annals of the New York Academy of Sciences
  • 1951
TLDR
Type or categories of scalp hairiness which can be used as standards for classitication and grading of the extent of common baldness are established and the relationship of scdp types to factors which influence the development of baldness is studied. Expand
Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
TLDR
It is concluded that finasteride causes profound decrease in prostatic dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia. Expand
Testosterone metabolism in the skin. A review of its function in androgenetic alopecia, acne vulgaris, and idiopathic hirsutism including recent studies with antiandrogens.
  • V. Price
  • Medicine
  • Archives of dermatology
  • 1975
TLDR
The hypothesis is submitted that a temporary, increased dihydrotestosterone formation at specific skin target sites at different ages causes the normal development of certain sexual characteristics, as well as the androgen-dependent skin disorders. Expand
Male hormone stimulation is prerequisite and an incitant in common baldness
TLDR
The author concludes that the predisposing factors, including congenital, are ineffective in production of seborrhea, acne vulgaris and premature alopeci in the absence of adequate gonadal hormone substance. Expand
Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia.
  • D. Whiting
  • Medicine
  • Journal of the American Academy of Dermatology
  • 1993
TLDR
Horizontal sections of scalp biopsy specimens in MPAA provide more diagnostic information than vertical sections and appear to have a predictive value for hair regrowth. Expand
The effect of finasteride in men with benign prostatic hyperplasia.
  • P. Walsh
  • Medicine
  • The Journal of urology
  • 1993
TLDR
The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction. Expand
Proscar: five-year experience.
TLDR
Treatment of BPH with finasteride for 5 years inhibits the progression of the disease with an excellent safety profile and represents a low-risk medical option for the treatment of symptomatic BPH. Expand
The effect of finasteride on prostate specific antigen: review of available data.
TLDR
To interpret serum PSA levels in men with BPH treated with finasteride for 6 months or longer, the serum PSI level should be multiplied by 2 and compared to either age-independent or age-specific upper limits of normal for serum PSC in untreated men withBPH. Expand
...
1
2
3
4
...